Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and cardiovascular risk reduction are among the new CKD management recommendations from the Kidney Disease: Improving Global Outcomes (KDIGO) organization.
“The last CKD guideline was published in 2012, and there have been so many exciting contributions to nephrology in the past years that the guideline required an update,” Magdalena Madero, MD, of the National Heart Institute in Mexico City, Mexico, told Medscape Medical News. “SGLT-2 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) are some of the new fascinating drugs that [have] modified the course of CKD.”
Madero is…